P PACIFIC BIOSCIENCES CALIF IN
| Market Cap | $404.68M |
| P/E Ratio | — |
| Forward P/E | -3.25 |
| Dividend Yield | — |
| Beta | 2.33 |
| 52W Range | $0.91 - $2.67 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| Polen Capital Management Polen Capital Management | 0.00% | $256.00K | 137,149 | Buy |
Insider Trading
| Insider Name of the company insider who made the trade 10 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Gibson James R IISee Remarks | Sale | 88,185 | $1.37 | $120.81K | 01 Apr 2026 | 01 Apr 2026 |
| Van Oene MarkSee Remarks | Sale | 6,504 | $1.51 | $9.85K | 03 Mar 2026 | 04 Mar 2026 |
| Farmer MicheleSee Remarks | Sale | 2,979 | $1.51 | $4.51K | 03 Mar 2026 | 04 Mar 2026 |
| HENRY CHRISTIAN OSee Remarks | Sale | 12,497 | $1.51 | $18.92K | 03 Mar 2026 | 04 Mar 2026 |
| Van Oene MarkSee Remarks | Sale | 55,107 | $1.63 | $89.77K | 18 Feb 2026 | 19 Feb 2026 |
| HENRY CHRISTIAN OSee Remarks | Sale | 140,874 | $1.63 | $229.48K | 18 Feb 2026 | 19 Feb 2026 |
| Farmer MicheleSee Remarks | Sale | 14,952 | $1.63 | $24.36K | 18 Feb 2026 | 19 Feb 2026 |
| Van Oene MarkSee Remarks | Sale | 129,790 | $1.58 | $204.55K | 17 Feb 2026 | 19 Feb 2026 |
| HENRY CHRISTIAN OSee Remarks | Sale | 331,793 | $1.58 | $522.91K | 17 Feb 2026 | 19 Feb 2026 |
| Farmer MicheleSee Remarks | Sale | 35,215 | $1.58 | $55.50K | 17 Feb 2026 | 19 Feb 2026 |
Frequently Asked Questions
What is PACB stock price today?
PACIFIC BIOSCIENCES CALIF IN (PACB) is currently trading at $1.34. The stock has a 52-week range of $0.91 to $2.67 and a market capitalization of $404.68M.
Is PACB a good stock to buy in 2026?
PACIFIC BIOSCIENCES CALIF IN has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of +12.6%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling PACB stock?
There have been 10 insider transactions for PACB in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has PACB stock performed over the past year?
PACIFIC BIOSCIENCES CALIF IN (PACB) has returned +12.6% over the past 12 months. The stock traded between $0.91 and $2.67 during this period, and is currently at $1.34.
Which hedge funds own PACB (PACIFIC BIOSCIENCES CALIF IN)?
1 tracked hedge funds currently hold PACB in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is PACB's market cap and valuation?
PACIFIC BIOSCIENCES CALIF IN (PACB) has a market capitalization of $404.68M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is PACB's revenue and profitability?
PACIFIC BIOSCIENCES CALIF IN reported revenue of $160.00M with net income of N/A and a profit margin of N/A. The stock has a beta of 2.33.
What sector is PACB in and who are its biggest institutional holders?
PACIFIC BIOSCIENCES CALIF IN (PACB) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.